Modality
Fusion Protein
MOA
IL-17i
Target
MET
Pathway
Angiogenesis
CholangiocarcinomaRett
Development Pipeline
Preclinical
~Dec 2012
→ ~Mar 2014
Phase 1
~Jun 2014
→ ~Sep 2015
Phase 2
~Dec 2015
→ ~Mar 2017
Phase 3
~Jun 2017
→ ~Sep 2018
NDA/BLA
Dec 2018
→ Jun 2026
NDA/BLACurrent
NCT03301276
1,722 pts·Rett
2018-12→2026-06·Not yet recruiting
NCT07478739
713 pts·Rett
2023-05→TBD·Active
2,435 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-06-243mo awayPh3 Readout· Rett
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
NDA/BLA
Not yet…
NDA/BLA
Active
Catalysts
Ph3 Readout
2026-06-24 · 3mo away
Rett
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03301276 | NDA/BLA | Rett | Not yet recr... | 1722 | DAS28 |
| NCT07478739 | NDA/BLA | Rett | Active | 713 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| ARG-3458 | Argenx | Preclinical | RET | |
| RVM-274 | Revolution Medicines | Phase 3 | MET | |
| Nidaratamab | Krystal Biotech | Preclinical | RET | |
| Doxazasiran | Axsome | Phase 1 | TIM-3 |